Vivian Y. Shi

Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

Vivian Y. Shi, Tina Bhutani, Luz Fonacier et al. · Journal of the American Academy of Dermatology · 2022 · 93 citations · Full text

Medicine, Dermatology, Pharmacotherapy +15

The <scp>pan‐JAK</scp> inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase <scp>IIb</scp> trial*

Margitta Worm, Jacob P. Thyssen, Sibylle Schliemann et al. · British Journal of Dermatology · 2022 · 88 citations · Full text

Medicine, Dermatology, Pharmacology +14

IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis

Lei Bao, Vivian Y. Shi, Lawrence S. Chan · Molecular Immunology · 2012 · 68 citations · Full text

Medicine, Dermatology, Immunology +16

IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: Relevant in the pathogenesis of atopic dermatitis

Lei Bao, Vivian Y. Shi, Lawrence S. Chan · Cytokine · 2012 · 66 citations · Full text

Medicine, Dermatology, Immunology +17

Topical probiotics: the unknowns behind their rising popularity

Griffin R. Lee, Melody Maarouf, Aleksi J. Hendricks et al. · Dermatology Online Journal · 2019 · 65 citations · Full text

Medicine, Dermatology, Pharmacology +13